Botteri F M, Ballmer-Hofer K, Rajput B, Nagamine Y
Friedrich Miescher-Institute, Basel, Switzerland.
J Biol Chem. 1990 Aug 5;265(22):13327-34.
Urokinase-type plasminogen activator (uPA) is expressed at higher levels in many transformed cells as compared with their non-transformed counterparts. The transformed phenotype is associated with changes in the cytoskeleton. Therefore, we have investigated whether alterations in the cytoskeleton can trigger changes in the expression of the uPA gene. To this end we analyzed the expression of the uPA gene following exposure of porcine kidney cells, LLC-PK1, to agents that modify the organization of specific components of the cytoskeleton. These cells exhibited increased uPA mRNA and protein after disruption of microtubules by colchicine or nocodazole treatment or after disruption of microfilaments by cytochalasin B treatment. Colchicine, nocodazole, and cytochalasin B did not cause alterations in the level of cAMP-dependent protein kinase in LLC-PK1 cells. In contrast, down-regulation of protein kinase C by phorbol myristate acetate, reduced, but did not fully prevent the induction of uPA mRNA when LLC-PK1 cells were subsequently exposed to colchicine, nocodazole, or cytochalasin B. Apparently, a signal transduction pathway in part involving protein kinase C but not cAMP-protein kinase mediates the regulatory changes at the transcriptional level of the uPA gene. Inhibition of protein synthesis by cycloheximide prior to the exposure of LLC-PK1 cells to colchicine, nocodazole, or cytochalasin B, largely prevented the induction of uPA mRNA.
与未转化的对应细胞相比,尿激酶型纤溶酶原激活剂(uPA)在许多转化细胞中的表达水平更高。转化表型与细胞骨架的变化有关。因此,我们研究了细胞骨架的改变是否会引发uPA基因表达的变化。为此,我们分析了猪肾细胞LLC-PK1在暴露于改变细胞骨架特定成分组织的试剂后uPA基因的表达情况。在用秋水仙碱或诺考达唑处理破坏微管后,或在用细胞松弛素B处理破坏微丝后,这些细胞的uPA mRNA和蛋白质水平均有所增加。秋水仙碱、诺考达唑和细胞松弛素B并未导致LLC-PK1细胞中cAMP依赖性蛋白激酶水平的改变。相反,当LLC-PK1细胞随后暴露于秋水仙碱、诺考达唑或细胞松弛素B时,佛波酯肉豆蔻酸酯乙酸盐对蛋白激酶C的下调减少了但并未完全阻止uPA mRNA的诱导。显然,一条部分涉及蛋白激酶C但不涉及cAMP蛋白激酶的信号转导途径介导了uPA基因转录水平的调节变化。在LLC-PK1细胞暴露于秋水仙碱、诺考达唑或细胞松弛素B之前,用放线菌酮抑制蛋白质合成,很大程度上阻止了uPA mRNA的诱导。